What is Prosidyan?
Founded in 2009, Prosidyan specializes in the development of synthetic bioactive bone graft substitutes. The company leverages proprietary bioactive glass fiber technology to provide advanced solutions for orthopedic and spinal surgery. Its product portfolio, which includes FIBERGRAFT BG Morsels, FIBERGRAFT BG Putty, and the collagen-based FIBERGRAFT BG Matrix, represents a significant shift toward synthetic alternatives in bone regeneration. By integrating its proprietary OSSIGLIDE carrier, Prosidyan has successfully navigated the regulatory landscape, securing multiple FDA clearances that validate its clinical efficacy and market readiness in the highly competitive biomaterials industry.
How much funding has Prosidyan raised?
Prosidyan has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Prosidyan
PPP
Public-Private Partnership
What's next for Prosidyan?
The infusion of capital from this late-stage funding round positions Prosidyan to scale its manufacturing capabilities and expand its commercial footprint. As the company transitions from a development-focused entity to a market-leading provider of synthetic bone grafts, strategic priorities will likely include deepening its penetration into the global orthopedic market and investing in clinical research to support the long-term performance of its bioactive glass fiber technology. The firm is well-positioned to capitalize on the growing demand for synthetic, non-allograft bone substitutes, ensuring sustained growth and competitive differentiation in the medical device sector.
See full Prosidyan company page
